Johnson & Johnson (NYSE:JNJ) is Welch & Forbes LLC’s 10th Largest Position

Welch & Forbes LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 738,404 shares of the company’s stock after selling 1,197 shares during the period. Johnson & Johnson makes up approximately 2.3% of Welch & Forbes LLC’s holdings, making the stock its 10th largest position. Welch & Forbes LLC’s holdings in Johnson & Johnson were worth $95,535,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Zions Bancorporation N.A. boosted its position in Johnson & Johnson by 0.4% during the second quarter. Zions Bancorporation N.A. now owns 20,173 shares of the company’s stock worth $2,810,000 after acquiring an additional 73 shares during the last quarter. Vishria Bird Financial Group LLC boosted its holdings in Johnson & Johnson by 3.0% in the second quarter. Vishria Bird Financial Group LLC now owns 2,736 shares of the company’s stock valued at $381,000 after acquiring an additional 80 shares during the last quarter. Deane Retirement Strategies Inc. boosted its holdings in Johnson & Johnson by 0.7% in the second quarter. Deane Retirement Strategies Inc. now owns 12,379 shares of the company’s stock valued at $1,724,000 after acquiring an additional 85 shares during the last quarter. Evanson Asset Management LLC boosted its holdings in Johnson & Johnson by 0.5% in the second quarter. Evanson Asset Management LLC now owns 17,870 shares of the company’s stock valued at $2,489,000 after acquiring an additional 85 shares during the last quarter. Finally, Gilman Hill Asset Management LLC lifted its stake in Johnson & Johnson by 1.1% in the second quarter. Gilman Hill Asset Management LLC now owns 8,137 shares of the company’s stock valued at $1,133,000 after buying an additional 85 shares during the period. Hedge funds and other institutional investors own 72.01% of the company’s stock.

Several equities analysts have weighed in on JNJ shares. Barclays started coverage on Johnson & Johnson in a research note on Friday, June 21st. They issued a “hold” rating and a $140.00 target price on the stock. Goldman Sachs Group set a $169.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research note on Tuesday, August 27th. Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 target price on the stock in a research note on Friday. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 target price on the stock. in a research note on Thursday, July 18th. Finally, Raymond James cut their target price on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 17th. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $151.00.

NYSE JNJ opened at $131.33 on Friday. The firm has a market cap of $341.03 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.18 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.33 and a quick ratio of 1.04. The stock’s 50-day moving average is $129.92 and its 200-day moving average is $134.97. Johnson & Johnson has a one year low of $121.00 and a one year high of $148.99.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping the Zacks’ consensus estimate of $2.42 by $0.16. The company had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. Johnson & Johnson’s revenue was down 1.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.10 earnings per share. Equities analysts anticipate that Johnson & Johnson will post 8.59 EPS for the current year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: How is a Moving Average Calculated?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit